Compare CCLD & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCLD | ARMP |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 146.0M | 125.7M |
| IPO Year | 2014 | N/A |
| Metric | CCLD | ARMP |
|---|---|---|
| Price | $3.04 | $5.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $1.50 | ★ $9.00 |
| AVG Volume (30 Days) | ★ 494.3K | 105.7K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $114,315,000.00 | $5,054,000.00 |
| Revenue This Year | $6.94 | $8.43 |
| Revenue Next Year | $18.66 | N/A |
| P/E Ratio | $39.39 | ★ N/A |
| Revenue Growth | ★ 2.97 | N/A |
| 52 Week Low | $1.14 | $0.90 |
| 52 Week High | $4.84 | $16.34 |
| Indicator | CCLD | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 47.42 | 41.88 |
| Support Level | $2.99 | $6.81 |
| Resistance Level | $3.19 | $7.40 |
| Average True Range (ATR) | 0.14 | 0.70 |
| MACD | 0.01 | -0.20 |
| Stochastic Oscillator | 38.89 | 4.48 |
CareCloud Inc delivers flexible, tech-enabled solutions for healthcare providers of all sizes and multi-specialties across the U.S. It is a healthcare technology company offering cloud-based solutions that simplify clinical, administrative, and financial workflows for medical practices of all sizes. Its comprehensive suite includes Electronic Health Records (EHRs), Practice Management, Revenue Cycle Management (RCM), Medical Billing, Telehealth, and Patient Experience solutions. The group helps practices increase efficiency, improve patient care, and drive sustainable growth-all while ensuring HIPAA compliance and seamless integration. The operating segments of the group are Healthcare IT, which is the key revenue-generating segment, and Medical Practice Management.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.